Parabilis Medicines, Inc. (PBLS) Revenue, Earnings & Financial Statements
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Parabilis Medicines, Inc. most recently reported annual revenue of $0, a net loss of $146.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Parabilis Medicines, Inc.: the most recent year shows a net loss of $146.0M.
Income Statement — 2 Years (USD millions)
Quarterly Results — Last 5 Quarters (USD millions)
Over the 2 years reported for Parabilis Medicines, Inc., borrowings decreased from $66.0M in 2024 to $59.0M in 2025, cash stood at $28.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 0.51 times.
Balance Sheet — 2 Years (USD millions)
For Parabilis Medicines, Inc., free cash flow in the latest year was negative at $124.0M.
Cash Flow Statement — 2 Years (USD millions)
Valuation & Return Ratios
Parabilis Medicines, Inc. (PBLS) financials — frequently asked questions
What is Parabilis Medicines, Inc.'s annual revenue?
Parabilis Medicines, Inc. (PBLS) reported annual revenue of $0 in its most recent fiscal year.
What is Parabilis Medicines, Inc.'s net profit?
Parabilis Medicines, Inc. (PBLS) reported a net loss of $146.0M in its most recent fiscal year.
What is PBLS EV/EBITDA?
Parabilis Medicines, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -26.81. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.